FIGURE 2 from Mathematical Modeling Identifies Optimum Palbociclib-fulvestrant Dose Administration Schedules for the Treatment of Patients with Estrogen Receptor–positive Breast Cancer
Year: 2023
Type: other
Abstract: A, B, Posterior prediction of the total cell count. Each panel shows the posterior predicted total number of live cells over 5 days for a specific combination of palbociclib and fulvestrant for −DOX (A) and +DOX (B) cells. The line represents the median posterior predicted live cell count value over 5 days and the gray shaded area corresponds to the 95% credible interval of the posterior predictive values. The datapoints represent the observed cell counts from the drug synergy experiments used to train the model. The concentration of palbociclib increases across the columns and is denoted at the top of each column; the concentration of fulvestrant increases down the rows and is denoted to the right of each row. The unit of drug concentrations is nmol/L. C, D, The posterior predictive number of cells in each phase of the cell cycle for −DOX (C) and +DOX (D) cells treated with fulvestrant and palbociclib in combination. Each panel corresponds to a specific dose of fulvestrant and palbociclib. The line represents the median posterior predictive value and the shaded area corresponds to the 95% credible interval of the posterior predictive values. The datapoints represent the observed cell phase counts from the cell-cycle analysis experiments used to train the model. The concentrations of fulvestrant and palbociclib increase across the columns and are denoted at the top of each column. Red, blue, and green represent the G0–G1, S, and G2–M phases, respectively. See Supplementary Fig. S5 and S6 for more sets of drug concentrations.
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4388728150